Compass Therapeutics Stock Buy Hold or Sell Recommendation
| CMPX Stock | USD 1.38 0.01 0.73% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Compass Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Compass Therapeutics given historical horizon and risk tolerance towards Compass Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Compass Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Compass Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide. In addition, we conduct extensive research on individual companies such as Compass and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Compass Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Compass |
Execute Compass Therapeutics Buy or Sell Advice
The Compass recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Compass Therapeutics. Macroaxis does not own or have any residual interests in Compass Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Compass Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Compass Therapeutics Trading Alerts and Improvement Suggestions
| Compass Therapeutics had very high historical volatility over the last 90 days | |
| Compass Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (42.49 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Compass Therapeutics currently holds about 132.02 M in cash with (40.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31. | |
| Compass Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 69.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Down -23.46 percent in 4 Weeks, Heres Why You Should You Buy the Dip in Compass Therapeutics, Inc. |
Compass Therapeutics Returns Distribution Density
The distribution of Compass Therapeutics' historical returns is an attempt to chart the uncertainty of Compass Therapeutics' future price movements. The chart of the probability distribution of Compass Therapeutics daily returns describes the distribution of returns around its average expected value. We use Compass Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Compass Therapeutics returns is essential to provide solid investment advice for Compass Therapeutics.
| Mean Return | 0.37 | Value At Risk | -5.92 | Potential Upside | 11.19 | Standard Deviation | 5.47 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Compass Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Compass Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Compass Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Compass Therapeutics back and forth among themselves.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 2.3 M | Cormorant Asset Management, Llc | 2024-06-30 | 2 M | State Street Corp | 2024-06-30 | 1.9 M | Baker Bros Advisors Lp | 2024-09-30 | 1.6 M | Northern Trust Corp | 2024-09-30 | 844.4 K | Monashee Investment Management Llc | 2024-09-30 | 500 K | Millennium Management Llc | 2024-06-30 | 433.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 335.8 K | Cm Management, Llc | 2024-09-30 | 310 K | Orbimed Advisors, Llc | 2024-06-30 | 22.4 M | Adage Capital Partners Gp Llc | 2024-06-30 | 11.1 M |
Compass Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (466K) | 38K | (1.8M) | (151.2M) | 27.0M | 28.3M | |
| Change In Cash | (32.2M) | 21.8M | 97.2M | (109.6M) | (10.7M) | (10.2M) | |
| Free Cash Flow | (32.2M) | (26.9M) | (21.2M) | (34.3M) | (40.6M) | (42.7M) | |
| Depreciation | 2.1M | 2.4M | 1.6M | 1.9M | 1.9M | 1.6M | |
| Other Non Cash Items | 116K | (960K) | 41K | (871K) | 6.0M | 6.3M | |
| Capital Expenditures | 466K | 106K | 1.6M | 212K | 30K | 28.5K | |
| Net Income | (34.7M) | (29.5M) | (82.2M) | (39.2M) | (42.5M) | (44.6M) | |
| End Period Cash Flow | 25.6M | 47.3M | 144.5M | 34.9M | 24.2M | 44.6M | |
| Change To Netincome | 1.1M | 4.9M | 54.6M | 5.3M | 6.0M | 5.7M |
Compass Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Compass Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Compass Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Compass stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.04 | |
β | Beta against Dow Jones | 3.20 | |
σ | Overall volatility | 5.48 | |
Ir | Information ratio | 0.05 |
Compass Therapeutics Volatility Alert
Compass Therapeutics exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Compass Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Compass Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Compass Therapeutics Fundamentals Vs Peers
Comparing Compass Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Compass Therapeutics' direct or indirect competition across all of the common fundamentals between Compass Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Compass Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Compass Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Compass Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Compass Therapeutics to competition |
| Fundamentals | Compass Therapeutics | Peer Average |
| Return On Equity | -0.32 | -0.31 |
| Return On Asset | -0.22 | -0.14 |
| Operating Margin | (65.23) % | (5.51) % |
| Current Valuation | 61.35 M | 16.62 B |
| Shares Outstanding | 137.59 M | 571.82 M |
| Shares Owned By Insiders | 12.04 % | 10.09 % |
| Shares Owned By Institutions | 69.19 % | 39.21 % |
| Number Of Shares Shorted | 1.79 M | 4.71 M |
| Price To Book | 1.37 X | 9.51 X |
| Price To Sales | 223.38 X | 11.42 X |
| EBITDA | (48.47 M) | 3.9 B |
| Net Income | (42.49 M) | 570.98 M |
| Cash And Equivalents | 132.02 M | 2.7 B |
| Cash Per Share | 1.31 X | 5.01 X |
| Total Debt | 1.73 M | 5.32 B |
| Debt To Equity | 0.03 % | 48.70 % |
| Current Ratio | 12.36 X | 2.16 X |
| Book Value Per Share | 1.01 X | 1.93 K |
| Cash Flow From Operations | (40.62 M) | 971.22 M |
| Short Ratio | 3.71 X | 4.00 X |
| Earnings Per Share | (0.35) X | 3.12 X |
| Target Price | 8.0 | |
| Number Of Employees | 32 | 18.84 K |
| Beta | 0.75 | -0.15 |
| Market Capitalization | 189.87 M | 19.03 B |
| Total Asset | 156.88 M | 29.47 B |
| Retained Earnings | (315.31 M) | 9.33 B |
| Working Capital | 146.08 M | 1.48 B |
| Net Asset | 156.88 M |
Note: Acquisition by Ferneau Philip of 30000 shares of Compass Therapeutics at 2.4 subject to Rule 16b-3 [view details]
Compass Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Compass . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Compass Therapeutics Buy or Sell Advice
When is the right time to buy or sell Compass Therapeutics? Buying financial instruments such as Compass Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Compass Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run IT Thematic Idea Now
IT
Information Technology (IT) companies and IT service providers across different domains. The IT theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize IT Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.